Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...

Guillain-Barré Syndrome (GBS) poses a diagnostic challenge due to its misleading symptoms, the lack of a definitive test, and ...

Background: Post-stroke fatigue is a common and debilitating issue, often linked to depression or neural damage. Emerging evidence suggests that myasthenia gravis (MG) may also play a role in ...

Dubai, United Arab Emirates - There's a lot of brain power that goes into speech. First, there's a thought or idea, which the ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...